Paradromics reports real-time communication in first Connexus participant
Source publication date
Summary
Paradromics said its first implanted participant used Connexus to communicate self-selected words as real-time text and synthesized speech. The work is part of the Connect-One early feasibility study under an FDA-approved investigational device exemption.
Editorial view
Editorial view: This is a useful case to track as testing moves toward self-directed communication.
Evidence and limitations
Company-reported early participant case. IDE approval is not marketing authorization or proof of general accuracy, long-term safety, or clinical benefit.